stockrow
Friday 6 November 2026
Export EWTX’s income statement to Excel — free account
Edgewise Therapeutics, Inc.
EWTX Healthcare Biotechnology
- EPS
- +2,846.5%
- Free cash flow
- −30.2%
Quarter to September 2026, against a year earlier
44.89
6.02
+15.49%
Follow EWTX
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(34.19%) | (38.14%) | (38.03%) | 92.15% | |
| (32.29%) | (36.18%) | (36.09%) | 85.43% | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(32.03%) | (35.58%) | (43.89%) | 61.76% | |
Free Cash Flow per Share |
(1.40) | (1.39) | (1.48) | (1.86) | |
Free Cash Flow |
(144.07) | (148.96) | (158.83) | (202.28) | |
Capital Expenditures |
(0.26) | (0.47) | (0.45) | (0.38) | |
| Other line items | |||||
Cash ROIC |
(13.69%) | (15.01%) | (17.48%) | (5.99%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.86 | 0.84 | 0.80 | (0.20) | |
Depreciation/Fixed assets |
(0.69) | (0.60) | (0.44) | (0.58) | |
Capex/Depreciation |
0.05 | 0.11 | 0.15 | 0.10 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.40) | (1.39) | (1.47) | (1.85) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026